

# **Developing Data and Computational Models to Enhance Risk Decisions**

## An Update on ToxCast and ExpoCast

Kevin M. Crofton
Deputy Director
National Center for Computational Toxicology



Dalian University
April 2015

Office of Research and Development National Center for Computational Toxicology

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the U.S. EPA

## **Outline**

#### The Problem

There are thousands and thousands of chemcials that have never been tested for hazardous effects

### Addressing the Problem

- Part 1 Chemicals
- Part 2 ToxCast & Tox21 Hazard estimates
  - Developing data high-throughput in vitro and QSAR
  - > Data interpretation Consensus model development
- Part 3 ExpoCast
  - Dosimetry estimating daily dose
  - High-throughput exposure predictions


### Putting it all together

Cost efficient and rapid prioritization

# Risk Assessment and the Chemical Universe A Long-Term Problem


- 1974 US NRC report
- Major challenge is too many chemicals and not enough data
- Total = 65,725
- No tox data = 46,000

#### US National Research Council, 1984






## 60,000 Chemicals Black dot = no data, Red dot = data\*




# Risk Assessment and the Chemical Universe

- Since 1984 some progress has been made
- Refined chemical universe
  - -TSCA Inventory = 75,000
  - -REACH Inventory = 150,000
  - US & Canadian estimates of about 30 thousand substances in active commercial use
- Accelerated chemical testing
  - ToxCast program
  - US Tox21 testing program

## High Priority Chemical Universe and Available Data 2010 Update





## Part 1

## **Hazard Predictions for Prioritization**

#### **Chemicals**

Two critical aspects to High-throughput bioactivity screening

- 1. Must have a highly curated chemical structure library
  - DSSTOX –chemicals database
    - 750k chemicals with CAS numbers
    - contains over structures for about 70%



- 2. Chemical Repository
  - Developed a chemical repository for about 4500 chemicals
  - Includes QA and QC metrics (e.g., analytical chemistry)
  - Allows for platting and shipping of 96 and 384 well-plates for testing
- Information Sources
  - DSSTOX <a href="http://www.epa.gov/ncct/dsstox">http://www.epa.gov/ncct/dsstox</a>
  - Chemical Library White paper on chemicals management
     <a href="http://epa.gov/ncct/toxcast/files/ToxCast%20Chemicals/ToxCast\_Chemicals\_QA\_QC\_Management\_%20141204.pdf">http://epa.gov/ncct/toxcast/files/ToxCast%20Chemicals/ToxCast\_Chemicals\_QA\_QC\_Management\_%20141204.pdf</a>

## Part 2


## **Hazard Predictions for Prioritization**

#### **ToxCast and Tox21**


- ToxCast EPA program
  - Multi-year research program started in 2007
  - Use automated in vitro chemical screening technologies to expose living cells or isolated proteins to chemicals where changes in biological activity may suggest potential toxic effects
  - Chemical library
    - ~3000 environmentally relevant chemicals <u>http://www.epa.gov/ncct/toxcast/</u>
- Tox21 Collaborative effort of US EPA, National Institutes of Health and Food and Drug Administration
  - aimed at developing better toxicity assessment methods using HTS.
  - Chemical library
    - ~10,000 chemicals, including environmental chemicals, food additives and pharmaceuticals <a href="http://www.ncats.nih.gov/research/reengineering/tox21/tox21.html">http://www.ncats.nih.gov/research/reengineering/tox21/tox21.html</a>



## **High-Throughput Screening (HTS)**



### ToxCast In Vitro Assays (>700 endpoints)



#### **Assay Provider**

ACEA
Apredica
Attagene
BioReliance
BioSeek
CeeTox
CellzDirect
Tox21/NCATS
NHEERL MESC
NHEERL Zebrafish
NovaScreen (Perkin Elmer)
Odyssey Thera
Vala Sciences

#### **Biological Response**

cell proliferation and death cell differentiation Enzymatic activity mitochondrial depolarization protein stabilization oxidative phosphorylation reporter gene activation gene expression (qNPA) receptor binding receptor activity steroidogenesis

#### **Target Family**

response Element
transporter
cytokines
kinases
nuclear receptor
CYP450 / ADME
cholinesterase
phosphatases
proteases
XME metabolism
GPCRs
ion channels

#### **Assay Design**

1536-well plate

viability reporter
morphology reporter
conformation reporter
enzyme reporter
membrane potential reporter
binding reporter
inducible reporter

#### **Readout Type**

single multiplexed multiparametric

#### **Cell Format**

cell free cell lines primary cells complex cultures free embryos

#### **Species**

human rat mouse zebrafish sheep boar rabbit cattle guinea pig

#### **Tissue Source**

Lung Breast Liver Vascular Skin Kidney Testis Cervix Uterus Brain Intestinal Spleen Bladder Ovary **Pancreas** Prostate Inflammatory Bone


#### **Detection Technology**

qNPA and ELISA
Fluorescence & Luminescence
Alamar Blue Reduction
Arrayscan / Microscopy
Reporter gene activation
Spectrophotometry
Radioactivity
HPLC and HPEC
TR-FRET

Office of Research and Development National Center for Computational Toxicology

# ToxCast & Tox21: Chemicals, Data and Release Timelines

| Set               | Chemicals | Assays | Endpoints | Completion | Available |
|-------------------|-----------|--------|-----------|------------|-----------|
| ToxCast Phase I   | 293       | ~600   | ~700      | 2011       | Now       |
| ToxCast Phase II  | 767       | ~600   | ~700      | 03/2013    | Now       |
| ToxCast E1K       | 800       | ~50    | ~120      | 03/2013    | Now       |
| Tox21             | ~9000     | ~80    | ~150      | Ongoing    | Ongoing   |
| ToxCast Phase III | ~900      | ~300   | ~300      | Ongoing    | 2014-2015 |





## **High Throughput In Vitro Test Methods**

- Half the assays can be part right all of the time,
   And some of the assays can be all right part of the time
   But all the assays can't be all right all of the time.\*
- Example: ToxCast currently has 18 assays that have readouts for different parts of ER signaling pathways
- Idea: Combine these using a pathways approach and develop a probabilistic predictive model based on all of the data, not just one assays

<sup>\*</sup> Apologies to A Lincoln & B Dylan

## Using Multiple Lines of Evidence to Predict ER Activity






Judson et al (unpublished)


Reference Chemical Classification

- 36 chemicals reviewed by ORD scientists
  - Inactive vs Active
  - Active –very weak, weak, moderate, or strong




Consensus Model "Receptor"

Demonstrates the ability to predict in vivo outcome



#### Model Agonist Score and Expert Calls



Judson et al (unpublished)

#### Addition of ER Structure-Based models

#### Problem:

- ToxCast data for only about 1800 chemicals for 18 assays and 8500 chemicals for ER and AR assays
- ER Expert System covers up to 70-80% of highest-priority 5000 EDSP chemicals
- Augment HTS with Expanded QSAR and docking models.
  - Allows for large universe of chemicals to be evaluated
  - Provides another way to evaluate HTS data
- Cooperative Estrogen Receptor Activity Prediction Project (CERAPP)
  - Collaborate with 10 expert QSAR and docking groups to generate consensus ER predictions for EDSP universe and beyond
  - Currently working to develop a curated list of ~30k structures

#### Part 3


# Estimating Exposure Dose From in vitro Experiments

**Reverse Toxicokinetics** 

# Reverse Toxicokinetics (In Vitro Dosimetry)


- Problem: How to estimate daily exposure dose from in vitro media concentration
- Use Reverse Toxicokinetics (RTK)
  - very simple 2 parameter PK models
  - in vitro measurements of disappearance of parent compound and serum binding values
- Provides scaling from concentration in which there is in vitro biological activity to in vivo activity dose (mg/kg/day)

## Adding Pharmacokinetics Reverse ToxicoKinetics (rTK)



- Combine experimental data w/ PK Model to estimate dose / concentration scaling
- RatCast: Same experiment, but with rat hepatocytes and plasma

## Combining in vitro activity and dosimetry



#### Part 4

## **High-Throughput Exposure Predictions**

# **ExpoCast HTP Exposure Predictions**


### Exposure science lags behind

 Most models require extensive information on production, use, fate and transport and rely on empirical data (no measurement = no exposure?)

### ExpoCast

- Exposure predictions based on pChem, production values, fate and transport, and product use categories (e.g., industrial, pesticide use, consumer personal care)
- Industrial vs consumer use
- Yields exposure estimates and Baysian confidence

# **Exposure Predictions for 7968 Chemicals & Comparison to NHANES**



- NHANES US National Study measures exposures in human serum and urine
- Chemicals currently monitored by NHANES are distributed throughput the predictions
- Shows accuracy of the prediction model

# **Putting It All Together For Rapid Prioritization**

# Putting It All Together HT Prioritization


#### Risk is the product of hazard and exposure

There are thousands of chemicals in commerce, most without enough data for risk evaluation

High throughput *in vitro* methods beginning to bear fruit on potential hazard for many of these chemicals

Methods exist for approximately converting these *in vitro* results to daily doses needed to produce similar levels in a human (IVIVE)

What can we say about exposure with the limited data we have?



Judson et al., (2011) Chemical Research in Toxicology

# Putting It All Together HT Prioritization


#### Risk is the product of hazard and exposure

There are thousands of chemicals in commerce, most without enough data for risk evaluation

High throughput *in vitro* methods beginning to bear fruit on potential hazard for many of these chemicals


Methods exist for approximately converting these *in vitro* results to daily doses needed to produce similar levels in a human (IVIVE)

What can we say about exposure with the limited data we have?



Judson et al., (2011) Chemical Research in Toxicology

## Combining 2<sup>nd</sup> Generation ExpoCast Exposure Preditions with Predicted Hazard



Predicted

Predicted Exposure

# Combining Bioactivity and Exposure For Estrogen Active Chemicals



ToxCast
Bioactivity
Converted to
mg/kg/day
with HTTK
(Wetmore et
al., 2012)

ExpoCast
Exposure
Predictions
(Wambaugh
et al., 2014)

#### **ToxCast Chemicals**

Prioritization = test the chemicals that might be the worst, first!

## 60,000 Chemicals Black dot = no data, Red dot = data\*

#### Progress!

- ToxCast Tox21 and ExpoCast have produced bioactivity and exposure estimates for ~8500 chemicals
- Currently being used for prioritization of endocrine disrupting chemicals

### Some of the Reactions We Get

- You don't include metabolism in you in vitro assays
- Assay (x) in your battery did not get the right answer for my chemical
- My assay disagrees with your assay (x), so your approach is flawed
- You can't test my favorite chemicals because of limitations in your methods (e.g., solvents, high LogP)
- You can't possibly do RTK modeling with only 2 parameters!
- You can't do HT Exposure predictions based on simple use models!
- If not this, then what? What other methods could we use for prioritization of thousands of chemicals?

## Alternative Approaches to Solving the Problem of How to Prioritize Thousands of Chemicals for Further Testing

